How does 1 kg of fat look like

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Major health organizations like the FDA, WHO, and EMA do not recommend ivermectin for the treatment or prevention of COVID-19, citing a lack of evidence for efficacy and concerns about safety when used outside of approved indications. Clinical trials have not demonstrated a significant benefit in preventing, treating, or reducing mortality from COVID-19.

Key Facts

The FDA has not approved or authorized ivermectin for use in preventing or treating COVID-19.
Numerous large-scale, randomized controlled trials have failed to show that ivermectin is effective against COVID-19.
The World Health Organization (WHO) recommends against using ivermectin outside of clinical trials for COVID-19.
Using ivermectin at doses higher than those approved for human use can be toxic and lead to serious health consequences.
Ivermectin is an antiparasitic drug approved for treating certain conditions caused by internal and external parasites in both humans and animals.

Overview

Ivermectin is an antiparasitic medication that has garnered significant attention, particularly in relation to its potential use in treating COVID-19. Originally developed to treat diseases caused by parasitic worms and ectoparasites, it has a well-established safety profile for these approved indications. However, its efficacy and safety for treating viral infections, especially SARS-CoV-2, remain a subject of intense debate and scientific scrutiny. Leading health authorities worldwide have consistently advised against its use for COVID-19 due to a lack of robust scientific evidence supporting its benefits and potential risks associated with its misuse.

The discussion around ivermectin's role in managing COVID-19 has been influenced by a complex interplay of preliminary studies, anecdotal reports, and public discourse. While some early in-vitro studies suggested potential antiviral properties, these findings have largely not translated into clinical benefit in well-designed human trials. Regulatory bodies and major medical organizations emphasize the importance of relying on evidence-based medicine, and thus far, ivermectin has not met the criteria for recommendation in COVID-19 treatment protocols.

How It Works

Antiparasitic Action: In its approved uses, ivermectin works by interfering with the nerve and muscle function of parasites. It binds to glutamate-gated chloride channels in invertebrate nerve and muscle cells, increasing the permeability of the cell membrane to chloride ions. This influx of chloride ions causes hyperpolarization of the cell, leading to paralysis and death of the parasite. This mechanism is highly specific to invertebrates and does not significantly affect mammals at approved doses.
Potential Antiviral Mechanisms (Unproven for COVID-19): Some laboratory studies have explored potential antiviral mechanisms for ivermectin, including inhibiting viral replication or interfering with viral entry into cells. However, these effects were observed at concentrations much higher than those achievable in humans with safe dosing. The relevance of these in-vitro findings to clinical outcomes in viral infections like COVID-19 is not established.
Off-Label Use Concerns: The exploration of ivermectin for COVID-19 has led to off-label prescribing and self-medication, including the use of veterinary formulations. These formulations can contain significantly higher doses than human-approved versions and may contain inactive ingredients that are not safe for human consumption. Such practices can lead to severe adverse effects, including nausea, vomiting, diarrhea, dizziness, and in extreme cases, seizures, coma, and death.
Immune Modulation (Hypothetical): Beyond direct antiviral effects, some researchers have hypothesized that ivermectin might possess immunomodulatory properties that could be beneficial in certain stages of viral infections. However, this remains a theoretical concept with no substantial clinical evidence to support it for COVID-19. The primary focus of scientific investigation has been on direct antiviral activity, which has not been proven in clinical settings.

Key Comparisons

Feature	Ivermectin (Approved Use)	Ivermectin (Unproven COVID-19 Use)
Indication	Treatment of parasitic infections (e.g., onchocerciasis, strongyloidiasis, scabies, head lice)	Prevention or treatment of COVID-19
Regulatory Status	Approved by FDA, EMA, and other health authorities for specific parasitic conditions.	Not approved or recommended by major health authorities (FDA, WHO, EMA) for COVID-19.
Evidence Base	Extensive clinical trials and decades of use demonstrate efficacy and safety for approved indications.	Lack of robust, large-scale, randomized controlled trials showing significant clinical benefit for COVID-19.
Dosage & Formulation	Specific, well-defined dosages for human use.	Varied and often inappropriate dosages, including veterinary formulations, leading to increased risk of toxicity.
Safety Profile	Generally safe when used as prescribed for approved conditions.	Increased risk of adverse events, including overdose and toxicity, when used off-label or at higher doses.

Why It Matters

Public Health Guidance: The clear guidance from major health organizations on ivermectin for COVID-19 is crucial for protecting public health. Relying on scientific consensus and regulatory recommendations helps to prevent the spread of misinformation and ensures that patients receive treatments that are proven to be safe and effective.
Patient Safety: The misuse of ivermectin, particularly in higher-than-approved doses or through veterinary preparations, poses significant health risks. Adhering to approved indications and consulting healthcare professionals for any treatment decisions is paramount for patient safety and to avoid potentially harmful side effects.
Resource Allocation: Focusing research and resources on treatments with a strong scientific basis is essential for combating diseases effectively. While investigating potential new therapies is important, diverting attention and resources to unproven treatments can hinder progress in finding genuinely effective solutions for public health crises.
Maintaining Trust: Clear and consistent communication from scientific and health authorities about the evidence for or against specific treatments helps to maintain public trust. When robust scientific data is presented transparently, it empowers individuals to make informed health decisions based on reliable information rather than speculation or unverified claims.

In conclusion, while ivermectin has a proven track record as an antiparasitic agent, its use for COVID-19 is not supported by current scientific evidence. Major health organizations strongly advise against its use for this purpose, emphasizing the availability of approved and effective treatments and the potential dangers of unproven therapies. Patients should always consult with their healthcare providers regarding any medical concerns or treatment options.